Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

LifeArc, one of the UK’s leading medical research charities, has signed a deal to license an ion channel drug discovery programme to Daiichi Sankyo Company, Limited.

Two researchers in a lab

The licensing deal successfully concludes a research collaboration between LifeArc, the University of Oxford's Nuffield Department of Clinical Neurosciences and Daiichi Sankyo. 

Small molecules, optimised as part of the programme, are capable of affecting the sensitivity of neurons, show efficacy in treating pain and will undergo further pre-clinical development.

Commenting on the announcement, Dr Justin Bryans, LifeArc’s Executive Director, Drug Discovery, said; 'We’re delighted to have been a part of an exciting collaboration that advanced basic research into a pre-clinical development programme within a major global pharmaceutical company. The success of this project is a testament to fantastic teamwork between all involved.' 

Under the terms of the deal Daiichi Sankyo acquires an exclusive worldwide license to a discovery stage programme of small molecules with the potential to develop into novel treatments for intractable pain.

Jeff Jerman, principal senior scientist and LifeArc project lead said; 'The small molecule drug candidates modulate the ion channel that underpins pain sensing.  LifeArc is using the experience and insight in this ion channel subfamily to explore the therapeutic potential of a range of other channels in the subfamily, including, but not exclusively, for pain.'

Summit Pharmaceuticals International Corporation served as advisor to LifeArc in connection with this transaction.

Similar stories

Research shows how the brain reorganises old memories when new ones are made

MRC BNDU Research

Researchers have discovered that the arrangement of existing memories in the brain is altered when we embed new memories

Capturing immune cells that colonise the brain to prevent disease progression in multiple sclerosis

Clinical Neurology Research

Researchers have revealed a disease-causing population of immune cells, which travel to the brain in patients with multiple sclerosis. They demonstrate how to trap these cells in the blood, which means they can be targeted to prevent disease progression.

New machine learning system developed to identify deteriorating patients in hospital

Anaesthetics Research

Researchers have developed a machine learning algorithm that could improve clinicians’ ability to identify hospitalised patients who need intensive care.

Accidental awareness in obstetric surgery under general anaesthesia more frequent than expected

Anaesthetics Research

The largest ever study of awareness during obstetric general anaesthesia shows around 1 in 250 women may be affected, and some may experience long-term psychological harm.